SCHEMBL4092061

SCHEMBL4092061

CCCc1nc2nc3ccccc3cc2c(=O)n1Cc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 5/20 0.61
PDE4B Q07343 5/20 0.61
PDE4C Q08493 5/20 0.61
PDE4D Q08499 5/20 0.61
TLR7 Q9NYK1 1/20 0.49
PDE3B Q13370 1/20 0.47
PDE3A Q14432 1/20 0.47
ALDH1A1 P00352 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
RAB9A P51151 2/20 0.47
NPC1 O15118 1/20 0.47
GAA P10253 1/20 0.47
PTGES O14684 3/20 0.46
AGTR1 P30556 1/20 0.46
AGTR2 P50052 1/20 0.46
MAPT P10636 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
LMNA P02545 2/20 0.45
RECQL P46063 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4750685 0.86 PDE4A (0.56) PDE4APDE4BPDE4CPDE4DTLR7
SCHEMBL2348949 0.83 PDE4A (0.85) PDE4APDE4BPDE4CPDE4DTLR7
SCHEMBL6512906 0.79 PDE4A (0.86) PDE4APDE4BPDE4CPDE4DTLR7
SCHEMBL4101714 0.78 PDE4A (0.44) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL13981738 0.78 PDE4A (0.44) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL5563021 0.76 PDE4A (0.64) PDE4APDE4BPDE4CPDE4DTLR7
SCHEMBL6518180 0.75 PDE4A (0.66) PDE4APDE4BPDE4CPDE4DTLR7
SCHEMBL4074953 0.75 PDE4A (0.56) PDE4APDE4BPDE4CPDE4DTLR7
SCHEMBL5353533 0.74 PDE4A (0.58) PDE4APDE4BPDE4CPDE4DTLR7
SCHEMBL5103773 0.73 PDE4A (0.60) PDE4APDE4BPDE4CPDE4DTLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090214529-A9 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2009-08-27 US disclosed
US-20090214529-A9 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2009-08-27 US disclosed
US-20090214529-A9 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2009-08-27 US disclosed
WO-2008147852-A1 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-12-04 WO disclosed
WO-2008147852-A1 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-12-04 WO disclosed
US-20080292626-A1 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-11-27 US disclosed
US-20080292626-A1 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-11-27 US disclosed
US-20080292626-A1 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090214529-A9 KINESIN INHIBITORS KIF5B, KIF5A, KIF5C PDE4A 2105/4885PDE4B 1790/4885PDE4C 1925/4885
US-20080292626-A1 KINESIN INHIBITORS KIF5B, KIF5A, KIF5C PDE4A 2105/4885PDE4B 1790/4885PDE4C 1925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.